Citations

Clear

1011 citation(s) found for "Barry, WT".

Abstract 712: Detection of lung cancer by assay of novel methylated DNA markers in plasma
Allawi, Hatim T. , Giakoumopoulos, Maria , Flietner, Evan, Oliphant, Austin, Volkmann, Carla J., Aizenstein, Brian, Sander, Tamara, Eckmayer, Drew, Strong, Ashley Poenitzsch, Gray, Melissa A. , Yab, Tracy C. , Taylor, William C., Midthun, David E. , Ahlquist, David A. , Lidgard, Graham P. , Strong, Ashley M. Poenitzsch , Berger, Barry M. , Mahoney, Douglas W. , Kisiel, John B.

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 712-712

10.1158/1538-7445.am2017-712 Get It

Abstract Purpose: Lung cancer is the leading cause of cancer deaths worldwide. Most present symptomatically at late stage with high lethality. Early detection reduces mortality but accurate and readily accessible tools for population screening are limited. By whole methylome sequencing, we have identified novel methylated DNA markers (MDMs) for lung cancer in tissue (Giakoumopoulos et al. ASCO 2016). Using top candidate MDMs in the present study, we now explore their clinical accuracy for lung cancer detection when assayed from plasma. Experimental Procedures: Archival plasmas from two independent study groups were tested in blinded fashion. Lung cancer cases and controls (apparently healthy smokers) for each group were balanced on age and sex (Group 1: 64 cases, 231 controls; Group 2: 23 cases, 80 controls). Using multiplex PCR followed by QuARTS (Quantitative Allele-Specific Real-time Target and Signal amplification) assay, a post-bisulfite quantification of MDMs on DNA extracted from plasma was performed. We selected 31 MDM candidates for initial evaluation in Group 1 (1 ml plasma/patient); top individual MDMs were subsequently tested in Group 2 to identify optimal MDM panels for lung cancer detection (2 ml/patient). Results: From Group 1 analyses, 13 high performance MDMs were selected for further testing (CYP26C1, SOBP, SUCLG2, SHOX2, ZDHHC1, NFIX, FLJ45983, HOXA9, B3GALT6, ZNF781, SP9, BARX1, EMX1) with individual areas under the receiver operator curve (AUCs) ranging from 0.593 to 0.939. Discrimination by individual MDMs was corroborated in Group 2 in which data was analyzed using two methods: a logistic regression fit and a regression partition tree approach. The logistic fit model identified a 4-marker panel (ZNF781, BARX1, EMX1, and SOBP) with an AUC of 0.96 and an overall sensitivity of 91% and 90% specificity. Analysis of the data using a regression partition tree approach identified 4 markers (ZNF781, BARX1, EMX1, and HOXA9) with AUC of 0.93 and an overall sensitivity of 96% and specificity of 94%. For both approaches, B3GALT6 was used as a standardizing marker of total DNA input. Conclusion: A panel of MDMs assayed in plasma achieved high sensitivity and specificity for all types of lung cancer. Further clinical evaluation and validation of this promising panel in larger patient groups are clearly indicated. Citation Format: Hatim T. Allawi, Maria Giakoumopoulos, Evan Flietner, Austin Oliphant, Carla Volkmann, Brian Aizenstein, Tamara Sander, Drew Eckmayer, Ashley Poenitzsch Strong, Melissa Gray, Barry Berger, Tracy Yab, William Taylor, Douglas Mahoney, John B. Kisiel, David E. Midthun, David A. Ahlquist, Graham P. Lidgard. Detection of lung cancer by assay of novel methylated DNA markers in plasma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 712. doi:10.1158/1538-7445.AM2017-712
Abstract 3093: Expression of DLL3 in metastatic melanoma, glioblastoma and high-grade extrapulmonary neuroendocrine carcinomas as potential indications for rovalpituzumab tesirine (Rova-T; SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody drug co
Saunders, Laura R. , Bheddah, Sheila, Isse, Kumiko, Fong, Sarah , Pysz, Marybeth A. , Beltran, Himisha , Sailer, Verena , Yin, Yu Zhi, Koshkin, Vadim S. , Grivas, Petros , Kosari, Farhad , Cheville, John C. , Moser, Justin C. , Flotte, Thomas J. , Hálfdánarson, Þorvarður R. , Leventakos, Konstantinos , Molina, Julian R. , Ball, Douglas W., Nelkin, Barry D. , Scaife, Courtney L. , Dylla, Scott J., Williams, Samuel A. , Puca, Loredana , Mosquera, Juan Miguel , Huang, Jiaoti , Armstrong, Andrew J. , García, Jorge , Magi‐Galluzzi, Cristina , Mansfield, Aaron S. , Shea, Jill , Halfdanarson, Thorvardur R

Mayo Clinic

Cancer Research | July 31, 2017 | Volume: 77 | Issue: 13_Supplement | Pages: 3093-3093

10.1158/1538-7445.am2017-3093 Get It

Abstract Expression of DLL3 was examined in additional tumor types, as it was found to be highly expressed in tumor-initiating cells (TIC) in small cell lung cancer (SCLC), where a DLL3-targeted antibody drug conjugate (ADC), rovalpituzumab tesirine (Rova-T; SC16LD6.5; Saunders et al. 2015 Sci Transl Med 7:302ra136)) exerted clinically meaningful anti-tumor effects in a phase I trial (Spigel et al. 2016 Lancet Oncology; In Press). DLL3 expression was profiled by qRT-PCR, ELISA and immunohistochemistry in multiple tumor types. Patient-derived xenografts (PDX) from melanoma and ovarian small cell carcinoma were established and used for efficacy studies to determine the ability of Rova-T to impact tumor growth and TIC frequency. DLL3 expression was seen in metastatic melanoma (55%), low grade gliomas (90%), glioblastoma (70%), medullary thyroid cancer (65%), carcinoids (33%), dispersed neuroendocrine tumors in the pancreas (9%), bladder (57%) and prostate (24%), testicular cancer (90%), and lung adenocarcinomas with neuroendocrine features (80%). Unlike SCLC, where DLL3 does not predict clinical outcome on standard therapies, DLL3 expression negatively correlates with overall survival in melanoma and small cell bladder cancer. In mice bearing DLL3 positive melanoma PDX, treatment with a single dose of Rova-T resulted in effective and durable responses (>100 days), which correlated with a significant impact on TIC frequency. Similarly, in mice bearing DLL3-positive ovarian small cell PDX, a single dose of Rova-T resulted in effective and durable responses (>100 days). Our results show that DLL3 is expressed in many neuroendocrine tumors (lung, ovarian, prostate, bladder, etc), metastatic melanoma, medullary thyroid cancer, low-grade gliomas and glioblastoma. Given pre-clinical results showing efficacy of Rova-T in melanoma and ovarian small cell carcinoma, as well as encouraging clinical data with Rova-T in patients with recurrent/refractory SCLC, clinical evaluation of Rova-T in DLL3-positive melanoma, glioblastoma, medullary thyroid cancer and other high-grade neuroendocrine carcinomas is warranted. A “basket” trial enrolling patients with DLL3-positive solid tumors is now recruiting patients (NCT02709889). Citation Format: Laura R. Saunders, Samuel A. Williams, Sheila Bheddah, Kumiko Isse, Sarah Fong, Marybeth A. Pysz, Himisha Beltran, Loredana Puca, Verena Sailer, Juan M. Mosquera, Yu Yin, Jiaoti Huang, Andrew J. Armstrong, Jorge Garcia, Cristina Magi-Galluzzi, Vadim Koshkin, Petros Grivas, Farhad Kosari, John Cheville, Justin C. Moser, Thomas J. Flotte, Thorvardur Halfdanarson, Aaron Mansfield, Konstantinos N. Leventakos, Julian R. Molina, Douglas W. Ball, Barry D. Nelkin, Jill E. Shea, Courtney L. Scaife, Scott J. Dylla. Expression of DLL3 in metastatic melanoma, glioblastoma and high-grade extrapulmonary neuroendocrine carcinomas as potential indications for rovalpituzumab tesirine (Rova-T; SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3093. doi:10.1158/1538-7445.AM2017-3093
Pulmonary Pressure Assessment with the Total Artificial Heart
Joyce, David L. , Redfield, Margaret M. , Kushwaha, Sudhir S. , Behfar, Atta , Borlaug, Barry A. , Daly, Richard C. , Sandhu, Gurpreet S. , Joyce, Lyle D., Behfar, Atta , Borlaug, Barry A

Mayo Clinic

ASAIO Journal | July 25, 2017 | Volume: 64 | Issue: 3 | Pages: e34-e36

10.1097/mat.0000000000000632 | PMID 28742532 Get It

Reversal of pulmonary hypertension has been observed in patients during a bridge to transplant with a left ventricular assist device. Total artificial heart (TAH) implant prevents subsequent right heart catheterization. Consequently, controversy exists over whether the prosthetic right ventricle improves or exacerbates pulmonary hypertension. A pulmonary artery (PA) pressure monitor was placed in two patients undergoing TAH implant, as a bridge to transplant. One patient had pulmonary hypertension at implant; the other had normal pulmonary pressures. Daily measurements were taken of systolic, diastolic, and mean PA pressures throughout support. Patient 1 received successful transplant after TAH support of 91 days. Systolic/diastolic (mean) PA pressures steadily decreased from 55/39 (28) mm Hg at implant to 29/18 (7) mm Hg currently. Patient 2 received support for 101 days before death due to abdominal ischemic complications. Pulmonary arterial pressures stayed consistent throughout this period, from 26/17 (20) mm Hg at implant to 23/13 (17) mm Hg at the time of death. These findings suggest that an implantable PA pressure monitor may be useful in optimizing hemodynamics and planning appropriate timing of transplant with TAH support.
Response by Obokata and Borlaug to Letter Regarding Article, “Role of Diastolic Stress Testing in the Evaluation for Heart Failure With Preserved Ejection Fraction: A Simultaneous Invasive-Echocardiographic Study”
Obokata, Masaru , Borlaug, Barry A. , Borlaug, Barry A , Obokata, Masaru

Mayo Clinic

Circulation | July 24, 2017 | Volume: 136 | Issue: 4 | Pages: 430-431

10.1161/circulationaha.117.029037 | PMID 28739816 Get It

Coping, Cognitive Emotion Regulation, and Burnout in Long-Term Care Nursing Staff: A Preliminary Study
Bamonti, Patricia M. , Conti, Elizabeth C., Cavanagh, Casey E. , Gerolimatos, Lindsay A., Gregg, Jeffrey J., Goulet, Carol , Pifer, Marisa, Edelstein, Barry A.

Mayo Clinic

Journal of Applied Gerontology | July 7, 2017 | Volume: 38 | Issue: 1 | Pages: 92-111

10.1177/0733464817716970 | PMID 28671027 Get It

Direct care workers (e.g., certified nursing assistants [CNAs]) employed in long-term care (LTC) are particularly vulnerable to the experience of burnout, yet they have received relatively less research attention compared to Licensed Practical Nurses and Registered Nurses. Within the burnout literature, evidence suggests that the deployment of certain coping strategies influences levels of burnout. The current study examined the extent to which coping (e.g., problem-focused, emotion-focused, and dysfunctional coping) and cognitive emotion regulation strategies (e.g., positive reappraisal) predicted burnout after controlling for covariates (age, sleep duration). Fifty-six CNAs were surveyed at four skilled nursing facilities in the United States. Dysfunctional coping was significantly associated with emotional exhaustion and depersonalization. Among cognitive emotion regulation strategies, positive reappraisal was significantly associated with depersonalization. Shorter sleep duration was associated with significantly greater depersonalization. Findings suggest the need to develop interventions for CNAs aimed at reducing dysfunctional coping strategies and increasing sleep duration.
Prostate Specific Antigen Cannot Distinguish Stage T1a (A1) Prostate Cancer from Benign Prostatic Hyperplasia
Monda, Jeffrey M., Oesterling, Joseph E., Barry, Michael J.

Mayo Clinic

Journal of Urology | June 30, 2017 | Volume: 151 | Issue: 5 | Pages: 1291-1295

10.1016/s0022-5347(17)35234-5 | PMID 7512660 Get It

Effects of Intensive BP Control in CKD
CHEUNG, ALFRED K., Rahman, Mahboob, Reboussin, David M. , Craven, Timothy E., Greene, Tom, Pl, Kimmel, Hawfield, Amret , Johnson, Karen , Lewis, Cora E., Oparil, S, Rocco, Michael V., Sink, Kaycee M. , Pk, Whelton, Wright, Jackson T., Jn, Basile, Bhatt, Udayan, Chertow, Glenn M., Chonchol, M, Freedman, Barry I., Haley, William, Ix, J H, Katz, Lois A., Killeen, Anthony A. , Ricardo, Ana C., Servilla, Karen, Wall, Barry, Wolfgram, Dawn, Yee, Jerry , Chertow, Glenn M. , Greene, Tom , Rocco, Michael V. , Rahman, Mahboob , Craven, Tim, Cushman, William C. , Lewis, Cora E. , Beddhu, Srinivasan , Bhatt, Udayan, Chang, Tara I. , Chonchol, Michel , Freedman, Barry I. , Haley, William E. , Ix, Joachim H. , Katz, Lois Anne , Papademetriou, Vasilios , Servilla, Karen S. , Wolfgram, Dawn F. , Greene, Tom , Rocco, Michael V

Mayo Clinic

Journal of the American Society of Nephrology | June 22, 2017 | Volume: 28 | Issue: 9 | Pages: 2812-2823

10.1681/asn.2017020148 | PMID 28642330 Get It

The appropriate target for BP in patients with CKD and hypertension remains uncertain. We report prespecified subgroup analyses of outcomes in participants with baseline CKD in the Systolic Blood Pressure Intervention Trial. We randomly assigned participants to a systolic BP target of <120 mm Hg (intensive group; n =1330) or <140 mm Hg (standard group; n =1316). After a median follow-up of 3.3 years, the primary composite cardiovascular outcome occurred in 112 intensive group and 131 standard group CKD participants (hazard ratio [HR], 0.81; 95% confidence interval [95% CI], 0.63 to 1.05). The intensive group also had a lower rate of all-cause death (HR, 0.72; 95% CI, 0.53 to 0.99). Treatment effects did not differ between participants with and without CKD ( P values for interactions ≥0.30). The prespecified main kidney outcome, defined as the composite of ≥50% decrease in eGFR from baseline or ESRD, occurred in 15 intensive group and 16 standard group participants (HR, 0.90; 95% CI, 0.44 to 1.83). After the initial 6 months, the intensive group had a slightly higher rate of change in eGFR (−0.47 versus −0.32 ml/min per 1.73 m 2 per year; P <0.03). The overall rate of serious adverse events did not differ between treatment groups, although some specific adverse events occurred more often in the intensive group. Thus, among patients with CKD and hypertension without diabetes, targeting an SBP<120 mm Hg compared with <140 mm Hg reduced rates of major cardiovascular events and all-cause death without evidence of effect modifications by CKD or deleterious effect on the main kidney outcome.
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty
Springer, Bryan D. , Dasa, Vinod , George, Michael , Gewurz‐Singer, Ora, Giles, Jon T. , Johnson, Beverly , Mandl, Lisa A. , Mont, Michael A. , Sculco, Peter K. , Sporer, Scott M. , Stryker, Louis S., Turgunbaev, Marat, Brause, Barry D. , Gililland, Jeremy M. , Goodman, Mark A. , Hurley-Rosenblatt, Arlene, Kirou, Kyriakos A. , Losina, Elena , MacKenzie, Ronald, Russell, Linda , Sah, Alexander P. , Miller, Amy S., Singh, Jasvinder A. , Yates, Adolph J. , Losina, Elena , George, Michael , Losina, Elena , Singh, Jasvinder A , Goodman, Susan M. , Guyatt, Gordon , Abdel, Matthew P. , Lee, Steve C. , Chen, Antonia F. , Michaud, Kaleb D. , Mikuls, Ted R. , Losina, Elena , Giles, Jon T , Kirou, Kyriakos A

Mayo Clinic

Arthritis Care & Research | June 16, 2017 | Volume: 69 | Issue: 8 | Pages: 1111-1124

10.1002/acr.23274 | PMID 28620917 Get It

Objective This collaboration between the American College of Rheumatology and the American Association of Hip and Knee Surgeons developed an evidence‐based guideline for the perioperative management of antirheumatic drug therapy for adults with rheumatoid arthritis (RA), spondyloarthritis (SpA) including ankylosing spondylitis and psoriatic arthritis, juvenile idiopathic arthritis (JIA), or systemic lupus erythematosus (SLE) undergoing elective total hip (THA) or total knee arthroplasty (TKA). Methods A panel of rheumatologists, orthopedic surgeons specializing in hip and knee arthroplasty, and methodologists was convened to construct the key clinical questions to be answered in the guideline. A multi‐step systematic literature review was then conducted, from which evidence was synthesized for continuing versus withholding antirheumatic drug therapy and for optimal glucocorticoid management in the perioperative period. A Patient Panel was convened to determine patient values and preferences, and the Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of evidence and the strength of recommendations, using a group consensus process through a convened Voting Panel of rheumatologists and orthopedic surgeons. The strength of the recommendation reflects the degree of certainty that benefits outweigh harms of the intervention, or vice versa, considering the quality of available evidence and the variability in patient values and preferences. Results The guideline addresses the perioperative use of antirheumatic drug therapy including traditional disease‐modifying antirheumatic drugs, biologic agents, tofacitinib, and glucocorticoids in adults with RA, SpA, JIA, or SLE who are undergoing elective THA or TKA. It provides recommendations regarding when to continue, when to withhold, and when to restart these medications, and the optimal perioperative dosing of glucocorticoids. The guideline includes 7 recommendations, all of which are conditional and based on low‐ or moderate‐quality evidence. Conclusion This guideline should help decision‐making by clinicians and patients regarding perioperative antirheumatic medication management at the time of elective THA or TKA. These conditional recommendations reflect the paucity of high‐quality direct randomized controlled trial data.
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty
Springer, Bryan D. , Dasa, Vinod , George, Michael , Gewurz‐Singer, Ora, Giles, Jon T. , Johnson, Beverly , Mandl, Lisa A. , Mont, Michael A. , Sculco, Peter K. , Sporer, Scott M. , Stryker, Louis S., Turgunbaev, Marat, Brause, Barry D. , Gililland, Jeremy M. , Goodman, Mark A. , Hurley-Rosenblatt, Arlene, Kirou, Kyriakos A. , Losina, Elena , MacKenzie, Ronald, Russell, Linda , Sah, Alexander P. , Miller, Amy S., Singh, Jasvinder A. , Yates, Adolph J. , Losina, Elena , George, Michael , Losina, Elena , Singh, Jasvinder A , Goodman, Susan M. , Guyatt, Gordon , Abdel, Matthew P. , Lee, Steve C. , Chen, Antonia F. , Michaud, Kaleb D. , Mikuls, Ted R. , Losina, Elena , Giles, Jon T , Kirou, Kyriakos A

Mayo Clinic

Arthritis & Rheumatology | June 16, 2017 | Volume: 69 | Issue: 8 | Pages: 1538-1551

10.1002/art.40149 | PMID 28620948 Get It

ObjectiveThis collaboration between the American College of Rheumatology and the American Association of Hip and Knee Surgeons developed an evidence‐based guideline for the perioperative management of antirheumatic drug therapy for adults with rheumatoid arthritis (RA), spondyloarthritis (SpA) including ankylosing spondylitis and psoriatic arthritis, juvenile idiopathic arthritis (JIA), or systemic lupus erythematosus (SLE) undergoing elective total hip (THA) or total knee arthroplasty (TKA).MethodsA panel of rheumatologists, orthopedic surgeons specializing in hip and knee arthroplasty, and methodologists was convened to construct the key clinical questions to be answered in the guideline. A multi‐step systematic literature review was then conducted, from which evidence was synthesized for continuing versus withholding antirheumatic drug therapy and for optimal glucocorticoid management in the perioperative period. A Patient Panel was convened to determine patient values and preferences, and the Grading of Recommendations Assessment, Development and Evaluation methodology was used to rate the quality of evidence and the strength of recommendations, using a group consensus process through a convened Voting Panel of rheumatologists and orthopedic surgeons. The strength of the recommendation reflects the degree of certainty that benefits outweigh harms of the intervention, or vice versa, considering the quality of available evidence and the variability in patient values and preferences.ResultsThe guideline addresses the perioperative use of antirheumatic drug therapy including traditional disease‐modifying antirheumatic drugs, biologic agents, tofacitinib, and glucocorticoids in adults with RA, SpA, JIA, or SLE who are undergoing elective THA or TKA. It provides recommendations regarding when to continue, when to withhold, and when to restart these medications, and the optimal perioperative dosing of glucocorticoids. The guideline includes 7 recommendations, all of which are conditional and based on low‐ or moderate‐quality evidence.ConclusionThis guideline should help decision‐making by clinicians and patients regarding perioperative antirheumatic medication management at the time of elective THA or TKA. These conditional recommendations reflect the paucity of high‐quality direct randomized controlled trial data.